236 related articles for article (PubMed ID: 11361051)
1. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients.
Venkataramanan R; Shaw LM; Sarkozi L; Mullins R; Pirsch J; MacFarlane G; Scheller D; Ersfeld D; Frick M; Fitzsimmons WE; Virji M; Jain A; Brayman KL; Shaked A
J Clin Pharmacol; 2001 May; 41(5):542-51. PubMed ID: 11361051
[TBL] [Abstract][Full Text] [Related]
2. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation.
Staatz C; Taylor P; Tett S
Nephrol Dial Transplant; 2001 Sep; 16(9):1905-9. PubMed ID: 11522877
[TBL] [Abstract][Full Text] [Related]
3. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
Staatz CE; Willis C; Taylor PJ; Tett SE
Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
[TBL] [Abstract][Full Text] [Related]
6. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
8. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.
Katari SR; Magnone M; Shapiro R; Jordan M; Scantlebury V; Vivas C; Gritsch A; McCauley J; Starzl T; Demetris AJ; Randhawa PS
Clin Transplant; 1997 Jun; 11(3):237-42. PubMed ID: 9193849
[TBL] [Abstract][Full Text] [Related]
10. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation.
Riva N; Dip M; Halac E; Cáceres Guido P; Woillard JB; Licciardone N; Chan D; Buendía J; Borgnia D; Bosaleh A; de Davila MT; Imventarza O; Schaiquevich P
Ther Drug Monit; 2018 Aug; 40(4):401-410. PubMed ID: 29621122
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of tacrolimus (FK506) in whole blood liver transplant recipients by PRO-TRAC enzyme-linked immunosorbent assay and microparticle enzyme immunoassay IMX methods.
Brunet M; Pou L; Torra M; López R; Rodamilans M; Corbella J
Ther Drug Monit; 1996 Dec; 18(6):706-9. PubMed ID: 8946669
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients.
MacFarlane GD; Venkataramanan R; McDiarmid SV; Pirsch JD; Scheller DG; Ersfeld DL; Fitzsimmons WE
Pediatr Transplant; 2001 Apr; 5(2):119-24. PubMed ID: 11328550
[TBL] [Abstract][Full Text] [Related]
13. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
Kuypers DR; Vanrenterghem Y
Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
[TBL] [Abstract][Full Text] [Related]
14. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.
Kershner RP; Fitzsimmons WE
Transplantation; 1996 Oct; 62(7):920-6. PubMed ID: 8878385
[TBL] [Abstract][Full Text] [Related]
15. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report.
Toraishi T; Takeuchi H; Nakamura Y; Konno O; Yokoyama T; Iwamoto H; Hama K; Hirano T; Unezaki S; Okuyama K; Shimazu M
Transplant Proc; 2012 Jan; 44(1):134-6. PubMed ID: 22310597
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus analysis: a comparison of different methods and matrices.
Warty V; Zuckerman S; Venkataramanan R; Lever J; Chao J; Mckaveney T; Fung J; Starzl T
Ther Drug Monit; 1995 Apr; 17(2):159-67. PubMed ID: 7542809
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation.
Min DI; Perry PJ; Chen HY; Hunsicker LG
Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147
[TBL] [Abstract][Full Text] [Related]
18. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation.
Staatz CE; Taylor PJ; Lynch SV; Tett SE
Liver Transpl; 2004 Apr; 10(4):506-12. PubMed ID: 15048793
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients.
Richards KR; Hager D; Muth B; Astor BC; Kaufman D; Djamali A
Transplantation; 2014 May; 97(10):986-91. PubMed ID: 24784360
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.
Sapir-Pichhadze R; Wang Y; Famure O; Li Y; Kim SJ
Kidney Int; 2014 Jun; 85(6):1404-11. PubMed ID: 24336032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
